ARTICLE | Clinical News
Ixense apomorphine sublingual tablets regulatory update
June 4, 2001 7:00 AM UTC
Takeda received European marketing authorization for Ixense to treat erectile dysfunction (ED). The MAA was submitted in November 1999. In July 2000, TAP Pharmaceutical Products Inc. (Lake Forest, Ill...